Clinical Trials Logo

HER-2 Gene Amplification clinical trials

View clinical trials related to HER-2 Gene Amplification.

Filter by:

NCT ID: NCT03613168 Completed - Cholangiocarcinoma Clinical Trials

Trastuzumab in HER2-positive Biliary Tract Cancer

BILHER
Start date: June 1, 2019
Phase: Phase 2
Study type: Interventional

Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer. The recent study showed that HER2 overexpression or amplification is noted about 5-15% of total biliary tract cancer patients. The aim of this study is to evaluate the efficacy and safety of trastuzumab in the combination of current standard gemcitabine plus cisplatin.

NCT ID: NCT03602079 Completed - Prostate Cancer Clinical Trials

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Start date: July 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

NCT ID: NCT01774851 Terminated - Stomach Cancer Clinical Trials

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Start date: January 2013
Phase: Phase 2
Study type: Interventional

To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone

NCT ID: NCT01304784 Completed - Clinical trials for HER-2 Gene Amplification

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.